Clinical trial

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

NCT07215962

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Nivolumab + ipilimumab Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Nivolumab + ipilimumab + platinum-based chemotherapy Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Other dual-immuno-oncology therapy with chemotherapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

Design: OBSERVATIONAL · Status: ACTIVE NOT RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeOBSERVATIONAL

Start date2024-11-22

PhaseN/A

Conditions

Non-small Cell Lung Cancer (NSCLC)unresolved

Interventions

Nivolumab + ipilimumabBIOLOGICAL

Nivolumab + ipilimumab + platinum-based chemotherapyBIOLOGICAL

Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapyBIOLOGICAL

Other dual-immuno-oncology therapy with chemotherapyBIOLOGICAL

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07215962 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.